CLOs on the Move

ZyStor Therapeutics

www.zystor.com

 
ZyStor Therapeutics is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.zystor.com
  • 10437 W Innovation Dr Ste 100
    Milwaukee, WI USA 53226
  • Phone: 414.727.9777

Executives

Name Title Contact Details

Similar Companies

RNL BioStar

RNL BioStar Inc. is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Premera

Premera is a Mountlake Terrace, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Triad Life Sciences

Triad Life Sciences completes A$25m funding round, anticipates ASX listing in coming months – Learn More >> Triad Life Sciences® introduces InnovaMatrix™Technology Platform, a next-generation extracellular matrix (ECM) product that advance...

Martek Biosciences Corporation

Martek Biosciences Corporation is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Aravive

Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival. Our technology, originated in the laboratories of Drs. Amato Giaccia and his colleagues at Stanford University, uses genetic screening to identify critical targets for the development of therapeutic molecules for cancer therapy while sparing healthy cells. This strategy is designed to enable us to interrupt oncogenic signals and, using our high-affinity decoy receptors, outcompete cancer`s ability to grow, metastasize and acquire resistance to treatments. We believe our unique cancer therapies may hold promise as a monotherapy or in combination with other cancer treatments, augmenting the anti-tumor activity of radiotherapy, chemotherapy, immuno-therapeutics and cancer vaccines. By targeting advanced or metastatic disease, our approach has the potential to significantly improve survival rates while simultaneously reducing toxicity in cancer patients.